108 related articles for article (PubMed ID: 36679930)
1. Durability of ChAdOx1 nCoV-19 (Covishield
Verma A; Goel A; Katiyar H; Tiwari P; Mayank ; Sana A; Khetan D; Bhadauria DS; Raja A; Khokher N; Shalimar ; Singh RK; Aggarwal A
Vaccines (Basel); 2022 Dec; 11(1):. PubMed ID: 36679930
[TBL] [Abstract][Full Text] [Related]
2. Serological Immune Response Following ChAdOx1 nCoV-19 Vaccine (Covishield
Goel A; Verma A; Tiwari P; Katiyar H; Aggarwal A; Khetan D; Mayank ; Kishore RVK; Kumar P; Singh TP; Sheikh S; Vaishnav M; Pathak P; Shalimar
Vaccines (Basel); 2022 Oct; 10(11):. PubMed ID: 36366346
[TBL] [Abstract][Full Text] [Related]
3. Antibody response to ChAdOx1 nCoV-19 (Covishield®) vaccine in people on maintenance hemodialysis.
Bhadauria DS; Tiwari P; Goel A; Katiyar H; Kaul A; Mayank ; Aggarwal A; Verma A; Khetan D; Yachha M; Behera MR; Yadav B; Agarwal K; Prasad N
Semin Dial; 2023; 36(6):477-482. PubMed ID: 36843062
[TBL] [Abstract][Full Text] [Related]
4. Antibody response after first and second-dose of ChAdOx1-nCOV (Covishield
Singh AK; Phatak SR; Singh R; Bhattacharjee K; Singh NK; Gupta A; Sharma A
Vaccine; 2021 Oct; 39(44):6492-6509. PubMed ID: 34600747
[TBL] [Abstract][Full Text] [Related]
5. Antibody Response to ChAdOx1 nCoV-19 (AZD1222) Vaccine in Kidney Transplant Recipients.
Bhadauria DS; Katiyar H; Goel A; Tiwari P; Kishore RVK; Aggarwal A; Verma A; Khetan D; Kaul A; Yachha M; Behera MR; Yadav B; Prasad N
Vaccines (Basel); 2022 Oct; 10(10):. PubMed ID: 36298558
[TBL] [Abstract][Full Text] [Related]
6. Humoral antibody kinetics with ChAdOx1-nCOV (Covishield™) and BBV-152 (Covaxin™) vaccine among Indian Healthcare workers: A 6-month longitudinal cross-sectional Coronavirus Vaccine-induced antibody titre (COVAT) study.
Singh AK; Phatak SR; Singh R; Bhattacharjee K; Singh NK; Gupta A; Sharma A
Diabetes Metab Syndr; 2022 Feb; 16(2):102424. PubMed ID: 35150961
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of two COVID-19 vaccines used in India: An observational cohort study in health care workers from a tertiary care hospital.
Arankalle V; Kulkarni-Munje A; Kulkarni R; Palkar S; Patil R; Oswal J; Lalwani S; Mishra AC
Front Immunol; 2022; 13():928501. PubMed ID: 36211366
[TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial.
Folegatti PM; Ewer KJ; Aley PK; Angus B; Becker S; Belij-Rammerstorfer S; Bellamy D; Bibi S; Bittaye M; Clutterbuck EA; Dold C; Faust SN; Finn A; Flaxman AL; Hallis B; Heath P; Jenkin D; Lazarus R; Makinson R; Minassian AM; Pollock KM; Ramasamy M; Robinson H; Snape M; Tarrant R; Voysey M; Green C; Douglas AD; Hill AVS; Lambe T; Gilbert SC; Pollard AJ;
Lancet; 2020 Aug; 396(10249):467-478. PubMed ID: 32702298
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Antibody Response Elicited by ChAdOx1 and BNT162b2 COVID-19 Vaccine.
Kang YM; Minn D; Lim J; Lee KD; Jo DH; Choe KW; Kim MJ; Kim JM; Kim KN
J Korean Med Sci; 2021 Nov; 36(46):e311. PubMed ID: 34845875
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 Antibody Response Following COVID-19 Vaccination, a Longitudinal Study.
Chavhan SS; Dhikale PT; Adsul BB; Gokhale CN; Ingale AR; Pawar PN; Jadhav N
Indian J Community Med; 2023; 48(4):539-543. PubMed ID: 37662139
[TBL] [Abstract][Full Text] [Related]
11. Antibody profile in post-vaccinated & SARS-CoV-2 infected individuals.
Patil R; Shanbhag S; Shankarkumar A; Madkaikar M
Indian J Med Res; 2022; 155(5&6):538-545. PubMed ID: 36124500
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
Li G; Cappuccini F; Marchevsky NG; Aley PK; Aley R; Anslow R; Bibi S; Cathie K; Clutterbuck E; Faust SN; Feng S; Heath PT; Kerridge S; Lelliott A; Mujadidi Y; Ng KF; Rhead S; Roberts H; Robinson H; Roderick MR; Singh N; Smith D; Snape MD; Song R; Tang K; Yao A; Liu X; Lambe T; Pollard AJ;
Lancet; 2022 Jun; 399(10342):2212-2225. PubMed ID: 35691324
[TBL] [Abstract][Full Text] [Related]
13. Superficial venous thrombosisas a possible consequence of ChAdOx1 nCoV-19 vaccine: two case reports.
Sah MK; Singh BM; Sinha P; Devkota P; Yadav SK; Shrestha J; Shrestha A
J Med Case Rep; 2022 May; 16(1):182. PubMed ID: 35524323
[TBL] [Abstract][Full Text] [Related]
14. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study.
Barin B; Kasap U; Selçuk F; Volkan E; Uluçkan Ö
Lancet Microbe; 2022 Apr; 3(4):e274-e283. PubMed ID: 35165669
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses.
Thiruvengadam R; Awasthi A; Medigeshi G; Bhattacharya S; Mani S; Sivasubbu S; Shrivastava T; Samal S; Rathna Murugesan D; Koundinya Desiraju B; Kshetrapal P; Pandey R; Scaria V; Kumar Malik P; Taneja J; Binayke A; Vohra T; Zaheer A; Rathore D; Ahmad Khan N; Shaman H; Ahmed S; Kumar R; Deshpande S; Subramani C; Wadhwa N; Gupta N; Pandey AK; Bhattacharya J; Agrawal A; Vrati S; Bhatnagar S; Garg PK;
Lancet Infect Dis; 2022 Apr; 22(4):473-482. PubMed ID: 34838183
[TBL] [Abstract][Full Text] [Related]
16. [Antibody Response After Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthcare Workers with and without Previous COVID-19 Infection: A Prospective Observational Study].
Özgür D; Tütüncü EE
Mikrobiyol Bul; 2022 Jan; 56(1):36-48. PubMed ID: 35088958
[TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of Covishield vaccine in patients with autoimmune rheumatic diseases.
Gupta V; Gupta VK; Bajwa NK; Sachdeva A; Garg R; Ghosh A
J Family Med Prim Care; 2024 May; 13(5):1904-1910. PubMed ID: 38948615
[TBL] [Abstract][Full Text] [Related]
18. Withholding methotrexate after vaccination with ChAdOx1 nCov19 in patients with rheumatoid or psoriatic arthritis in India (MIVAC I and II): results of two, parallel, assessor-masked, randomised controlled trials.
Skaria TG; Sreeprakash A; Umesh R; Joseph S; Mohan M; Ahmed S; Mehta P; Oommen SE; Benny J; Paulose A; Paul A; George J; Sukumaran A; Babu SS; Navas S; Vijayan A; Joseph S; Nalianda KK; Narayanan K; Shenoy P
Lancet Rheumatol; 2022 Nov; 4(11):e755-e764. PubMed ID: 36320825
[TBL] [Abstract][Full Text] [Related]
19. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
20. Reactogenicity and Immunogenicity of the ChAdOx1 nCOV-19 Coronavirus Disease 2019 Vaccine in South Korean Healthcare Workers.
Hyun J; Park Y; Song YG; Han SH; Park SY; Kim SH; Park JS; Jeon SY; Lee HS; Lee KH
Yonsei Med J; 2022 Dec; 63(12):1078-1087. PubMed ID: 36444543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
